GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Cyclically Adjusted Price-to-FCF

Alk-Abello AS (OCSE:ALK B) Cyclically Adjusted Price-to-FCF : (As of Jul. 05, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Alk-Abello AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Cyclically Adjusted Price-to-FCF Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alk-Abello AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 639,719.39 3,143.13 1,094.76 - -

Competitive Comparison of Alk-Abello AS's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Alk-Abello AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Alk-Abello AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Alk-Abello AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Alk-Abello AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.501/120.2000*120.2000
=1.501

Current CPI (Mar. 2025) = 120.2000.

Alk-Abello AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.398 100.300 -0.477
201509 -0.223 100.200 -0.268
201512 0.590 99.800 0.711
201603 0.663 100.200 0.795
201606 0.306 100.600 0.366
201609 -0.103 100.200 -0.124
201612 0.005 100.300 0.006
201703 -0.570 101.200 -0.677
201706 -1.662 101.200 -1.974
201709 -0.782 101.800 -0.923
201712 -0.283 101.300 -0.336
201803 -0.312 101.700 -0.369
201806 -0.593 102.300 -0.697
201809 -0.538 102.400 -0.632
201812 0.278 102.100 0.327
201903 0.000 102.900 0.000
201906 -0.602 102.900 -0.703
201909 -0.147 102.900 -0.172
201912 0.578 102.900 0.675
202003 0.095 103.300 0.111
202006 0.140 103.200 0.163
202009 -0.423 103.500 -0.491
202012 0.548 103.400 0.637
202103 0.406 104.300 0.468
202106 0.200 105.000 0.229
202109 0.096 105.800 0.109
202112 0.237 106.600 0.267
202203 0.155 109.900 0.170
202206 0.252 113.600 0.267
202209 0.027 116.400 0.028
202212 -0.136 115.900 -0.141
202303 0.271 117.300 0.278
202306 -0.514 116.400 -0.531
202309 0.427 117.400 0.437
202312 1.007 116.700 1.037
202403 1.062 118.400 1.078
202406 0.725 118.500 0.735
202409 0.722 118.900 0.730
202412 -2.873 118.900 -2.904
202503 1.501 120.200 1.501

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello AS  (OCSE:ALK B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Alk-Abello AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines